Status dystonicus and Hallervorden-Spatz disease: Treatment with intrathecal baclofen and pallidotomy

Journal of Paediatrics and Child Health

Volumn 40, Issue 5-6, 2004, Pages 322-325

  Kyriagis, M ^a   Grattan Smith, P ^b   Scheinberg, A ^a   Teo, C ^c   Nakaji, N ^d   Waugh, M ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c PRINCE OF WALES PRIVATE HOSPITAL   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dystonia; Hallervorden Spatz disease; Intrathecal baclofen and pallidotomy

Indexed keywords

BACLOFEN; SEDATIVE AGENT; SPASMOLYTIC AGENT;

ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; DRUG MEGADOSE; DRUG RESPONSE; DYSTONIA; ENDOTRACHEAL INTUBATION; EXTRAPYRAMIDAL SYSTEM; GAIT; GENE MUTATION; GLOBUS PALLIDUS; HALLERVORDEN SPATZ DISEASE; HOSPITALIZATION; HUMAN; INTELLECTUAL IMPAIRMENT; INTENSIVE CARE UNIT; MALE; MORBIDITY; MORTALITY; MUSCLE SPASM; PALLIDOTOMY; PRIORITY JOURNAL; SCHOOL CHILD; SURGICAL TECHNIQUE;

BACLOFEN; CHILD; COMBINED MODALITY THERAPY; DYSTONIC DISORDERS; GLOBUS PALLIDUS; HALLERVORDEN-SPATZ SYNDROME; HUMANS; INJECTIONS, SPINAL; MAGNETIC RESONANCE IMAGING; MALE; MUSCLE RELAXANTS, CENTRAL; TREATMENT OUTCOME;

EID: 3042558081     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2004.00374.x     Document Type: Article

References (29)

1. Marsden CD, Marion M-H, Quinn N. The treatment of status dystonicus in children and adults. J. Neurol. Neurosurg. Psych. 1984; 47: 1166-73.
2. Narayan RK, Loubser PG, Jankovic J, Donovan WH, Bontke CF. Intrathecal Baclofen for intractable axial dystonia. Neurology 1991; 41: 1141-2.
3. Vaamonde J, Narbona J, Weiser R, Garcia MA, Brannan T, Obeso JA. Dystonic Storms: A Practical Management Problem. Clin. Neuropharmoc. 1994; 17: 344-7.
4. Manji H, Howard RS, Miller DH et al. Status dystonicus: the syndrome and its management. Brain 1998; 121: 243-52.
5. Dalvi A, Fajn S, Ford B. Intrathecal baclofen in the treatment of dystonic storm. Mov. Disord. 1998; 13: 611-12.
6. Ostergaard JR, Christensen T, Hansen KN. In vivo diagnosis of Hallervorden-Spatz disease. Dev. Med. Neurol. 1995; 37: 827-33.
7. Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden-Spatz syndrome. Arch. Neurol. 1974; 30: 70-83.
8. Swaimann KF. Hallervorden-Spatz syndrome. In: Gilman S, Goldstein GW, Waxman SG, eds. Neurobase, 4th edn. San Diego: Arbor Publishing, 1998.
9. Singhi PD, Mitra S. Hallervorden-Spatz disease: Late infantile type. J. Child Neuro. 1997; 12: 281-2.
10. Pena J, Molina O, Cardoza J. Hallervorden-Spatz disease: Two new early childhood onset cases. J. Child. Neuro. 2000; 15: 30-2.
11. Angelini L, Nardocci N, Rumi V, Zorzi C, Strada L, Savoiardo M. Hallervorden-Spatz disease: clinical and MRI study of 11 cases diagnosed in life. J. Neurol. 1992; 239: 417-25.
12. Savoiardi M, Halliday WC, Nardocci N et al. Hallervorden-Spatz disease MR and pathologic findings. AJNR 1993; 14: 155-62.
13. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz Syndrome. Nature Genet. 2001; 28: 345-9.
14. Shevell M. Racial hygiene, active euthanasia, and Julius Hallervorden. Neurology 1992; 42: 2214-19.
15. Gordon N. Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome). Eur. J.Paediatr. Neurol. 2002; 6: 243-7.
16. Teo C. Stereotactic Surgery for Idiopathic Cerebral Palsy. Krauss JK, Janovich J, Grossman R, eds. Surgery Forparkinson's Disease and Movement Disorders. Philadelphia: Lippincott Williams & Wilkins, 2001; 410-15.
17. Gilmartin R, Bruce D, Storrs B et al. Intrathecal Baclofen for management of spastic cerebral palsy: multicenter trial. J. Child Neurol. 2000; 15: 71-7.
18. Albright AL, Barry MJ, Shafron DH, Ferson SS. Intrathecal baclofen for generalised dystonia. Dev. Med. Neurol. 2001; 43: 652-7.
19. Ford B, Greene P, Louis ED et al. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch. Neurol. 1996; 53: 1241-6.
20. Walker RH, Danisi FO, Swope DM, Goodman RR, Germano IM, Brin MF. Intrathecal baclofen for dystonia, benefits and complications during six years of experience. Mov. Disord. 2000; 15: 1242-7.
21. Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov. Disord. 2001; 16: 1201-3.
22. Engrand N, Guerot E, Roumba A, Vilain G. The efficacy of intrathecal baclofen in severe tetanus. Anaesthiology 1999; 90: 1773-6.
23. Becker R, Sure U, Petermeyer M, Bertalanffy H. Continuous intrathecal baclofen infusion alleviates autonomic dysfunction in patients with severe supraspinal spasticity. J. Neurol. Neurosurg. Psych. (Letter) 1999; 66: 114.
24. Obeso JA, Rodriguez-Oroz MC, Rodriguez M et al. Pathophysiologic basis of surgery for Parkinson's Disease. Neurology 2000; 55 (Suppl. 6): S7-S12.
25. Vitek JL, Chockkan V, Zhang J-Y et al. Neuronal activity in the basal ganglia with generalized dystonia and hemiballismus. Ann. Neurol. 1999; 46: 22-35.
26. Ondo WG, Desaloms M, Jankovic J, Grossman RG. Pallidotomy for generalized dystonia. Mov. Disord. 1998; 13: 693-8.
27. Tsukamoto H, Inui K, Taniike M et al. A case of Hallervorden-Spatz disease: Progressive and intractable dystonia controlled by bilateral thalamotomy. Brain Dev. 1992; 14: 269-72.
28. Justesen CR, Penn RD, Kroin JS, Egel RT. Stereotactic pallidotomy in a child with Hallervorden-Spatz disease. J. Neurosurg. 1999; 90: 551-4.
29. Gannau A, Castelnau PA, Cif L et al. Treatment of dystonia due to pantothenate kinase associated neurodegeneration (PKAN) by Gpi stimulation (DBS). Mov. Disord. 2002; 17: S308.